Skip to content

The Effect of Blood on the PC Ratio During Pregnancy

The Effect of Blood on the Protein to Creatine Ratio During Pregnancy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05434845
Enrollment
20
Registered
2022-06-28
Start date
2022-06-19
Completion date
2022-12-19
Last updated
2022-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proteinuria in Pregnancy

Brief summary

This study will examine the effect if blood on the the protein to creatine (PC) ratio in pregnant patients by adding blood to urine samples.

Detailed description

The Purpose of the Research: The purpose of this study is to examine the effect of blood on the protein to creatine (PC) ratio in pregnant patients. The Scientific or Scholarly Rationale: The PC ratio is used to diagnosis proteinuria in pregnancy. It is thought that blood in the urine will cause the PC ratio to be elevated but there are no current studies to prove this hypothesis. The Procedures to be Performed: Upon presentation to the Labor and Delivery Triage or the Antepartum Unit, patients will be enrolled in the study. Urine collection that is not needed for medical workup will be collected and saved, and an extra 8 mLs of blood will be drawn during routine lab collection by phlebotomy team. Additional lab costs will be covered by Marshall Obstetrics & Gynecology. Lab protocol: Divide urine into 4 different specimen cups with 20 mLs of urine each to measure urinalysis (UA) and PC ratio: 1. UA and PC ratio on original sample 2. UA and PC ratio with 1 mL of whole blood added 3. UA and PC ratio with 2 mL of whole blood added 4. UA and PC ratio with 5 mL of whole blood added Subjects medical records will be reviewed for past obstetrical history after consent to be in the study. The Risks and Potential Benefits of the Research: Risks: 8 mLs of additional maternal blood will be drawn for study purposes. Possible risks could include pain, bleeding, fainting, bruising, infection, or hematoma (blood clot under the skin) at the injection site. Please note that routine blood would be drawn regardless of study enrollment. Benefits: Our hypothesis is that the PC ratio will be elevated by contamination with blood. It is unknown if this hypothesis is correct. Complete Inclusion/Exclusion Criteria (may be submitted separately if extensive): Inclusion criteria includes patients presenting to Labor and Delivery Triage or Antepartum Unit at Cabell Huntington Hospital between the ages of 18 and approximately 45 years and gestational age of \>20 weeks. Exclusion criteria includes pre-existing proteinuria (excess protein in the urine) or hematuria (blood in the urine).

Interventions

OTHERBlood draw

An additional 8 mL of blood will be drawn during routine lab collection

Sponsors

University at Buffalo
CollaboratorOTHER
Marshall University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Intervention model description

Divide urine into 4 different specimen cups with 20 mLs of urine each to measure urinalysis (UA) and PC ratio: 1. UA and PC ratio on original sample 2. UA and PC ratio with 1 mL of whole blood added 3. UA and PC ratio with 2 mL of whole blood added 4. UA and PC ratio with 5 mL of whole blood added

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Labor and Delivery Triage or Antepartum Unit at Cabell Huntington Hospital between the ages of 18 and approximately 45 years and gestational age of \>20 weeks

Exclusion criteria

* pre-existing proteinuria (excess protein in the urine) or hematuria (blood in the urine)

Design outcomes

Primary

MeasureTime frameDescription
To measure the PC ratio after whole blood has been serially added6 monthsThe PC ratio is used to diagnose proteinuria in pregnancy. Our goal is to determine if blood causes the PC ratio to be elevated.

Countries

United States

Contacts

Primary ContactJesse Cottrell, MD
cottrellj@marshall.edu304-691-1400
Backup ContactMorgan Ruley, MS
kelley115@marshall.edu304-691-1458

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026